The Importance of Genotype Variation Beyond Different Antiplatelet Therapy in Nonresponder Patients  by Sardella, Gennaro & Calcagno, Simone
J A C C V O L . 6 4 , N O . 3 , 2 0 1 4 Letters
J U L Y 2 2 , 2 0 1 4 : 3 3 2 – 4
333Dr. Cecere and colleagues also point out that no
effect (p ¼ 0.89) was observed in approximately
43% of patients given intravenous hydration. That
is probably not valid, and is too early a conclusion,
because subgroup analysis was usually underpow-
ered. A nonsigniﬁcant result does not mean no effect.
We think a more appropriate way is to have an
interaction test, and as mentioned in the preceding
text, the test assured us that rosuvastatin was con-
sistently effective among patients with or without
hydration.
We admit that the point estimate of the rosuvas-
tatin effect observed in patients with hydration was
less signiﬁcant. Whether rosuvastatin can provide an
add-on effect in pure hydration patients needs
further investigation. We also admit that hydration
remains the cornerstone of the prevention of CI-AKI
based on accumulated evidence in recent years.
In summary, we think our conclusion of “rosuvas-
tatin signiﬁcantly reduced the risk of CI-AKI in pa-
tients with DM and CKD undergoing arterial contrast
medium injection” remains valid in a population with
hydration or without hydration as a whole.*Yaling Han, MD, PhD
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Genotype Variation
Beyond Different
Antiplatelet Therapy in
Nonresponder PatientsWe read with great interest the recently published
paper on prasugrel or high-dose clopidogrel for high
platelet reactivity (HPR) in the Journal (1). Using theMultiplate analyzer (Roche Diagnostics, Mannheim,
Germany), the authors described how in patients
with acute coronary syndrome (ACS), with HPR,
switching therapy from clopidogrel to prasugrel
reduces thrombotic and bleeding events to a level
similar to those without HPR compared with high-
dose clopidogrel.
As is known, the therapeutic effectiveness of clo-
pidogrel is conditional upon its variability in its an-
tiplatelet effect, which is inﬂuenced by numerous
factors both genotypic (e.g., speciﬁc mutations in
cytochrome P450 CYP2C19) and phenotypic (e.g.,
patient presentation with ACS). It has been de-
monstrated unequivocally that genotype testing for
mutations in the clopidogrel metabolic pathway
can identify patients who are poor responders
and are at higher risk for subsequent ischemic events
(2). Either increasing the dose of clopidogrel or
substitution of other more potent agents not
affected by the CYP2C19 pathway in patients with
these mutations can lower platelet reactivity (PR)
(3,4). Encouraged by these results, we also analyzed
the superior efﬁcacy of prasugrel to reduce the
PR compared with a double dose of clopidogrel,
and the correlation with genotype assessment. We
showed the importance of CYP2C19*2 genotyping
(5), describing the superiority of prasugrel over a
double clopidogrel dose in patients carrying the
CYP2C19*2 loss-of-function allele, while observing
a similar efﬁcacy of the 2 treatments in noncarriers
of the CYP2C19*2 loss-of-function allele. PR was
signiﬁcantly lower (p ¼ 0.045) for prasugrel in
carriers, whereas no differences were observed in
noncarriers (p ¼ 0.575), but no one remained a poor
responder to prasugrel (p ¼ 0.003), whereas, despite
a double clopidogrel dose, carriers always showed
HPR.
It would be interesting to know the genotyping
assay results of the all-comer patients enrolled in the
2 arms of this nonrandomized study to show the
incidence of the CYP2C19*2 loss-of-function allele. In
fact, the presence of this genotype variation could
inﬂuence the superiority of prasugrel showed by
Aradi et al. (1) over a high dose of clopidogrel. In our
opinion, this is a central characteristic for a
nonrandomized study to obtain 2 more similar
populations to reach their aim and to evaluate the
clinical and pharmacodynamic impact of using ADP–
P2Y12 receptor inhibitors.
Finally, considering the high number of ST-
segment elevation myocardial infarctions in this
study, some concerns could arise about the clopi-
dogrel utilization even if with a double dose and
independently from PR responsiveness; in this
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334subset of patients, the best choice could be the new
antiplatelet agents, either prasugrel or ticagrelor.*Gennaro Sardella, MD
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Variation Beyond Different Antiplatelet
Therapy in Nonresponder PatientsWe thank Drs. Sardella and Calcagno for their interest
in our paper (1). Following their prior publication (2),
they emphasize the importance of genotyping for the
CYP2C19*2 allele to deﬁne the pharmacodynamic
beneﬁt from prasugrel or double-dose clopidogrel in
patients with high platelet reactivity (HPR).
Although we share the belief that there is robust
evidence to declare that clopidogrel-treated patients
harboring CYP2C19*2 alleles are at higher risk for
stent thrombosis and mortality after percutaneous
coronary intervention (PCI) (3), we would be more
cautious to derive deﬁnite conclusions from a
subgroup of a study including 32 patients, which the
authors themselves declared “not powered for an
additive genetic model” (2).
To give an accurate answer to the authors’ ques-
tion, we had genotyping results available from the
ﬁrst 69 acute coronary syndrome (ACS) patients
with HPR. Based on the results, the proportions ofCYP2C19*2 carriers were exactly the same in both HPR
groups (HPRþprasugrel 46.2% vs. HPRþclopidogrel
46.6%), corroborating that the beneﬁt of prasugrel
over high-dose clopidogrel was not inﬂuenced by
differences in genotype status.
Finally, the authors claim it unethical to use
clopidogrel in patients with ST-segment elevation
myocardial infarction (STEMI). In current European
practice guidelines, prasugrel and ticagrelor are
preferred over clopidogrel in all ACS patients, not
only in case of STEMI (4,5). However, the guide-
lines also add that clopidogrel still holds a Class I
indication when prasugrel and ticagrelor are not
available. Similar to many countries in the world,
prasugrel and ticagrelor were not available in
Hungary for all ACS patients at the time of the
registry, and many clinicians were convinced that
using high-dose clopidogrel might effectively
replace the costly new P2Y12 inhibitors. Our ﬁndings
are therefore important to show that irrespective of
the genotype status, high-dose clopidogrel is asso-
ciated with a 3-fold higher risk for mortality or stent
thrombosis compared with prasugrel in ACS patients
with HPR.*Dániel Aradi, MD, PhD
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